DataVXBiomaterials ResearchPaper
journal article·2022-09-30Open access

Treatment of bladder cancer by geoinspired synthetic chrysotile nanocarrier-delivered circPRMT5 siRNA

Chunping Yu, Yi Zhang, Ning Wang, Wensu Wei, Ke Cao, Qun Zhang, Peiying Ma, Dan Xie, Pei Wu, Biao Liu, Jiahao Liu, Wei Xiang, Xing Hu, Xuewen Liu, Jianfei Xie, Jin Tang, Zhi Long, Long Wang, Hongliang Zeng, Jianye Liu

Biomaterials Research· Volume 26· Issue 1
Publisher pageOpen full text
Source abstract

Abstract

Abstract Background Circular RNAs (circRNAs) have important functions in many fields of cancer biology. In particular, we previously reported that the oncogenic circRNA, circPRMT5 , has a major role in bladder cancer progression. Therapy based on circRNAs have good prospects as anticancer strategies. While anti-circRNAs are emerging as therapeutics, the specific in vivo delivery of anti-circRNAs into cancer cells has not been reported and remains challenging. Methods Synthesized chrysotile nanotubes (SCNTs) with a relatively uniform length (~ 200 nm) have been designed to deliver an siRNA against the oncogenic circPRMT5 (si-circPRMT5) inhibit circPRMT5. In addition, the antitumor effects and safety evaluation of SCNTs/si-circPRMT5 was assessed with a series of in vitro and in vivo assays. Results The results showed that SCNTs/si-circPRMT5 nanomaterials prolong si-circPRMT5’s half-life in circulation, enhance its specific uptake by tumor cells, and maximize the silencing efficiency of circPRMT5 . In vitro, SCNTs encapsulating si-circPRMT5 could inhibit bladder cancer cell growth and progression. In vivo, SCNTs/si-circPRMT5 inhibited growth and metastasis in three bladder tumor models (a subcutaneous model, a tail vein injection lung metastatic model, and an in situ model) without obvious toxicities. Mechanistic study showed that SCNTs/si-circPRMT5 regulated the miR-30c/SNAIL1/E-cadherin axis, inhibiting bladder cancer growth and progression. Conclusion The results highlight the potential therapeutic utility of SCNTs/si-circPRMT5 to deliver si-circPRMT5 to treat bladder cancer.
Source: crossref · Quality: baseline

Research context

Nanomaterials

OpenAlex topics: Circular RNAs in diseases · Extracellular vesicles in disease · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Urology, The Third Xiangya Hospital of Central South University, No.138, Tongzipo Road, Changsha 410013, Hunan, China.

Department of Urology, Sun Yat-sen University Cancer Center, No. 651, Dongfeng Road East, Guangzhou 510060, Guangdong, China.

State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, No. 651, Dongfeng Road East, Guangzhou 510060, Guangdong, China.

School of Minerals Processing and Bioengineering, Central South University, No. 932, Lushan South, Changsha 410083, Hunan, China.

Department of Onology, The Third Xiangya Hospital of Central South University, No.138, Tongzipo Road, Changsha 410013, Hunan, China.

Department of Radiotherapy, The First Affiliated Hospital of Sun Yat-sen University, 58 Zhongshan 2nd Road, Guangzhou 510080, Guangdong, China.

Department of Operation Center, The Second Xiangya Hospital of Central South University, People’s Middle Road, Changsha 410008, Hunan, China.

Department of Nursing, The Third Xiangya Hospital of Central South University, No.138, Tongzipo Road, Changsha 410013, Hunan, China.

Research Institute of Chinese Medicine, Hunan Academy of Chinese Medicine, No.58, Lushan Road, Changsha 410000, Hunan, China.

Funding

Natural Science Foundation of Hunan Province · Huxiang Young Talents Plan Project of Hunan Province · High-Tech Industry of Science and Technology Innovation Leadership Project of Hunan Province

References (37)

Show source-provided references
1. 10.1016/j.eururo.2016.06.01010.1016/j.eururo.2016.06.010 ↗
2. 10.3322/caac.2133810.3322/caac.21338 ↗
3. 10.1016/j.eururo.2012.08.01010.1016/j.eururo.2012.08.010 ↗
4. 10.1016/j.eururo.2019.08.01610.1016/j.eururo.2019.08.016 ↗
5. 10.1016/j.eururo.2020.03.05510.1016/j.eururo.2020.03.055 ↗
6. 10.1002/advs.20200337610.1002/advs.202003376 ↗
7. 10.1038/s41576-019-0158-710.1038/s41576-019-0158-7 ↗
8. 10.1016/j.molcel.2014.08.01910.1016/j.molcel.2014.08.019 ↗
9. 10.1016/j.cell.2014.09.00510.1016/j.cell.2014.09.005 ↗
10. 10.1038/onc.2017.36110.1038/onc.2017.361 ↗
11. 10.1016/j.canlet.2018.01.01110.1016/j.canlet.2018.01.011 ↗
12. 10.1158/1078-0432.CCR-18-127010.1158/1078-0432.CCR-18-1270 ↗
13. 10.1038/3588810.1038/35888 ↗
14. 10.1021/acsnano.6b0719510.1021/acsnano.6b07195 ↗
15. 10.1002/advs.20160004610.1002/advs.201600046 ↗
16. 10.1016/j.canlet.2016.03.04510.1016/j.canlet.2016.03.045 ↗
17. Tatiparti K Sau S Kashaw SK Iyer AK. siRNA delivery strategies: a comprehensive review of recent developments. Nanomaterials (Basel). 2017;7(4):77.10.3390/nano7040077 ↗
18. Li X Liu CX Xue W Zhang Y Jiang S Yin QF et al. Coordinated circRNA biogenesis and function with NF90/NF110 in viral infection. Mol Cell. 2017;67(2):214–227.e7.10.1016/j.molcel.2017.05.023 ↗
19. 10.1186/s40824-019-0166-x10.1186/s40824-019-0166-x ↗
20. 10.1038/s41573-019-0012-910.1038/s41573-019-0012-9 ↗
21. 10.1186/s40824-019-0175-910.1186/s40824-019-0175-9 ↗
22. 10.1038/nrd261410.1038/nrd2614 ↗
23. 10.1021/acs.estlett.6b0017410.1021/acs.estlett.6b00174 ↗
24. 10.1002/adfm.20070027810.1002/adfm.200700278 ↗
25. Steinberg GD, Brendler CB, Ichikawa T, Squire RA, Isaacs JT. Characterization of an N-methyl-N-nitrosourea-induced autochthonous rat bladder cancer model. Cancer Res. 1990;50(20):6668–6674. 1:CAS:528:DyaK3cXmt1ylur4%3D
26. 10.1097/01.ju.0000135816.46544.7410.1097/01.ju.0000135816.46544.74 ↗
27. 10.1016/j.biomaterials.2021.12073710.1016/j.biomaterials.2021.120737 ↗
28. 10.1038/nrd274210.1038/nrd2742 ↗
29. 10.1186/1476-4598-9-2010.1186/1476-4598-9-20 ↗
30. 10.1111/cas.1276210.1111/cas.12762 ↗
31. 10.1186/s13045-018-0569-510.1186/s13045-018-0569-5 ↗
32. Wu SY Lopez-Berestein G Calin GA Sood AK. RNAi therapies: drugging the undruggable. Sci Transl Med. 2014;6(240):240ps7.10.1126/scitranslmed.3008362 ↗
33. 10.1158/2159-8290.CD-12-042910.1158/2159-8290.CD-12-0429 ↗
34. 10.1016/j.addr.2007.03.00510.1016/j.addr.2007.03.005 ↗
35. 10.1038/nchembio83910.1038/nchembio839 ↗
36. 10.1371/journal.pbio.002002810.1371/journal.pbio.0020028 ↗
37. 10.1002/adma.20160149810.1002/adma.201601498 ↗